Paul Ryb to lead dedicated ophthalmology practice at Outcome Capital

Outcome Capital has appointed Paul Ryb as managing director to lead its newly established ophthalmology practice.

Ryb has more than 30 years of experience in investment banking, capital markets and venture capital, and has spent the past 15 years focused on ophthalmic innovation. His previous roles include managing director positions at Royal Bank of Scotland (NatWest Group) and other major banks. He has also served on boards including the NHS and Royal National Institute of the Blind. He was vice chair of the Macular Society UK for 12 years and sits on the investment committee for Fight for Sight, the UK’s largest supporter of ophthalmic research grants.

He holds an economics degree from the University of Manchester and is certified by the UK’s Financial Conduct Authority. Outside his professional work, he is a world and British champion in visually impaired tennis and holds a black belt in Xen-Do kickboxing.

Oded Ben-Joseph, managing partner at Outcome Capital, said: ‘This appointment aligns with Outcome’s strategy to address the rapidly growing ophthalmology segment through the first dedicated ophthalmology practice in the market to address eye disease, the leading cause of disability.’

According to Ben-Joseph, Ryb’s insight will strengthen the firm’s capabilities to assist innovative ophthalmology companies in their demand for venture support and implement de-risking strategies, such as broader access to strategic opportunities, robust market intelligence, and seamless deal structuring.

‘Paul has already exemplified these strengths, notably through his role in the Bausch + Lomb acquisition of ELIOS Vision, and in his support of numerous financings for ophthalmic ventures in collaboration with key strategics and venture capitalists,’ he added.

Commenting on his new role, Ryb said: ‘Establishing such a differentiated and specialised Ophthalmic Investment Banking Advisory Group will allow us to deliver real patient outcomes and move closer to solving one of the world’s greatest unmet needs – sight-loss.

‘By integrating my experience with Outcome’s track record and deep expertise in ophthalmology for sourcing innovation, financing and successful exits, we are uniquely positioned to deliver on our mission to support the most promising ophthalmology innovation programmes through every stage of development and ultimately drive real patient outcomes.’